Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

    NEXT STORY
    Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
    PREV STORY
    Molecular Diagnostic Market To Reach USD 17.08 Billion By 2026 | Reports And Data
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes

    author_avatar
    NASDAQ Market News

    Publishing of Orion Corporation’s Financial Statement Release for 2017 on 7 February 2018

      ORION CORPORATION     PRESS RELEASE   24 JANUARY 2018 at 11.45 A.M. EET  Publishing of Orion ...

    author_avatar
    NASDAQ Market News

    AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps

    author_avatar
    NASDAQ Market News